THIOTEPA

Post-LOE

thiotepa

Gland Pharma

ANDAINTRACAVITARY, INTRAVENOUS, INTRAVESICALPOWDER

Approved

Mar 2020

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

THIOTEPA (thiotepa) by Gland Pharma is alkylating activity [moa]. Approved for alkylating drug [epc]. First approved in 2020.

Drug data last refreshed 21h ago

Mechanism of Action

Alkylating Activity

Pharmacologic Class:

Alkylating Drug

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (2)

NCT00450983Phase 2Terminated

Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases

Started Dec 2006

1 enrolled

Graft Versus Host DiseaseLeukemiaMyelodysplastic Syndromes

NCT00238433Phase 2Completed

Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma

Started Mar 2005

37 enrolled

Lymphoma

Company

Worked on THIOTEPA at Gland Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.